US Futures Mixed Ahead of Inflation Data
8:38AM ET 6/10/2022 MT NewswiresUS stock futures are mixed during Friday's premarket session ahead of monthly inflation figures, with the Consumer Price Index for May expected to rise...
Quotes Snapshot > TCRT
Alaunos Therapeutics Inc TCRT:NASDAQ
Last Price$1.24NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22
Today's Change0.00(0.00%)
Bid (Size)$1.21 (8)
Ask (Size)$1.26 (3)
Day Low / High$1.15 - 1.26
Volume1.7 M
Read more news Recent News
Top Premarket Gainers
7:59AM ET 6/10/2022 MT NewswiresRise Education Cayman (REDU) gained more than 240% after a change its American depositary shares ratio to 10 shares per ADS from 2 shares became effective...
--Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight
7:22AM ET 5/04/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Alaunos Therapeutics Doses First Patient in Phase 1/2 Trial of TCR-T Cell Therapy in Solid Tumors
10:49AM ET 5/02/2022 MT NewswiresAlaunos Therapeutics (TCRT) said Monday it has dosed the first patient in a phase 1/2 trial of TCR-T cell therapy for patients with solid tumors. The...
View all Commentary and Analysis
Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q1 2022 Results - Earnings Call Transcript
12:31PM ET 5/16/2022 Seeking AlphaShould Biotech Be On The Critical List?
9:30AM ET 5/11/2022 Seeking AlphaAlaunos Therapeutics, Inc. (TCRT) Kevin Boyle on Q4 2021 Results - Earnings Call Transcript
11:38AM ET 3/30/2022 Seeking AlphaZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript
7:45PM ET 11/08/2021 Seeking AlphaCompany Profile
Business DescriptionAlaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX. View company web site for more details
| Address | 8030 El Rio Street Houston, Texas 77054 |
| Phone | +1.346.355.4099 |
| Number of Employees | 48 |
| Recent SEC Filing | 06/27/2022 8-K |
| Chief Executive Officer & Director | Kevin S. Boyle |
| Executive Vice President-Operations | Eleanor M. de Groot |
| Chief Financial Officer | Timothy M. Cunningham |
| Vice President-Research & Development | Drew Deniger |
Company Highlights
| Price Open | $1.20 |
| Previous Close | $1.24 |
| 52 Week Range | $0.41 - 2.75 |
| Market Capitalization | $267.8 M |
| Shares Outstanding | 216.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/12/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.30 |
| Beta vs. S&P 500 | N/A |
| Revenue | $146.0 K |
| Net Profit Margin | -16,830.40% |
| Return on Equity | -101.43% |
Analyst Ratings as of 05/03/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |